Journal article
Novel Targeted Agents and Immunotherapy in Breast Cancer
Ingrid A Mayer, Rebecca Dent, Tira Tan, Peter Savas, Sherene Loi
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | American Society of Clinical Oncology | Published : 2017
DOI: 10.14694/EDBK_175631
Abstract
The treatment of breast cancer is generally determined according to breast cancer subtype: hormone receptor-positive (luminal), triple-negative (basal-like), and HER2-overexpressing breast cancer. Recent years have seen the development of exciting novel and potent therapeutics based on molecular pathways, immune modulation, and antibody conjugates. In this article, we cover new and emerging therapeutic areas and ongoing clinical trials that may result in further improvements in breast cancer outcomes.